eye
report strong print driven top-lin bottom-lin beat
find guidanc conserv total revenu guidanc consensu mainli
driven approxim price headwind guidanc soliri
also current consensu estim soliri guidanc impact
headwind due enrol competitor trial sinc
patient continu enrol increas sinc
earli surpris headwind includ onetim
benefit due soliri order time adjust soliri estim
accordingli adjust non-gaap ep updat po
due higher tax rate near-term soliri headwind
reiter buy rate strong underli volum growth soliri
phase data pnh come next
sustain strategi complement franchis investor focus
phase read-out paroxysm nocturn hemoglobinuria trial
power non-interior normal ldh biomark diseas defin
achiev ldh valu within laboratori normal rang percentag
patient achiev transfus avoid conserv assum lower rate
hemolysi seen real world suggest bar superior may
high due low event rate said believ base case non-inferior
favor trend numer advantag achiev plan
releas data nave switch studi data arriv could
month apart initi subcutan trial plan initi trial
technolog qm treatment regimen
pipelin updat track
soliri relaps neuromyel optica spectrum disord phase data expect
remain cautiou trial indic riski due lack
clear understand diseas pathophysiolog phase data
atyp hemolyt urem syndrom expect
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani market
soliri monoclon antibodi therapi
treatment ultra-rar diseas includ
paroxysm nocturn hemoglobinuria pnh
compani also market strensiq treatment
hypophosphatasia kanuma lal-d
focu sever life threaten ultra rare
rate buy expect industri
growth compani market product soliri
success launch new product
strensiq kanuma see upsid risk street
estim addit pipelin
momentum creat news flow
price object base discount cash flow analysi use
wacc termin growth rate
downsid risk failur meet expect soliri sale and/or launch
strensiq asfotas alfa kanuma lal-d govern drug price
focu ultra-orphan product failur advanc key pipelin product includ
soliri new indic
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
